Navigation Links
Stemedica Requests Pre-IND Meeting With FDA
Date:8/21/2009

Stemedica Cell Technologies, Inc. USA, a leader in adult stem cell research and manufacturing, has requested a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration ("FDA") to discuss a proposed IND to use Stemedica's proprietary line of allogeneic mesenchymal bone marrow cells (adult human) as a treatment for ischemic stroke.

San Diego, CA (PRWEB) August 21, 2009 -- Stemedica Cell Technologies, Inc. USA, a leader in adult stem cell research and manufacturing, has requested a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration ("FDA") to discuss a proposed IND to use Stemedica's proprietary line of allogeneic mesenchymal bone marrow cells (adult human) as a treatment for ischemic stroke.

Stroke is a leading cause of adult impairment, with 20% of stroke survivors requiring institutional care after 3 months and up to 30% severely and permanently disabled. The only approved treatments of acute ischemic stroke involves restoring blood flow to the affected region by using thrombolytics or mechanical devices that physically remove clots. However, the use of thrombolytics (tPA) is limited due to the therapeutic window of < 3-6 hours post onset of stroke symptoms such that only a small fraction of stroke patients receive this therapy.

"Following a stroke, there is little therapy to offer patients to promote recovery other than physical, occupational, and speech therapy," said Nikolai Tankovich, MD, PhD, President & Chief Medical Officer. "Treatment with allogeneic mesenchymal bone marrow cells may offer new hope to patients with chronic neurological or age-related, neurodegenerative diseases."

Allogeneic mesenchymal bone marrow cells are obtained from donors by extracting bone marrow and are expanded at Stemedica's cGMP compliant facility, which is licensed by the California Department of Public Health, Food and Drug Branch. "Stemedica's facility will manufacture clinical grade stem cells as it prepares for FDA approval of an IND to begin clinical trials," said Maynard Howe, PhD, Vice Chairman and CEO of Stemedica.

About Stemedica Cell Technologies, Inc.
Stemedica Cell Technologies Inc. (www.stemedica.com) is a specialty biopharmaceutical company that is committed to the development and manufacturing of best-in-class adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and human clinical trials. The company is currently developing regulatory pathways for stroke and wound repair. Stemedica is headquartered in San Diego, California.

For more information regarding Stemedica Cell Technologies, Inc. contact Dave McGuigan at dmcguigan (at) stemedica.com.

# # #

Read the full story at http://www.prweb.com/releases/Stemedica-Stroke/PRE-IND-FDA/prweb2776804.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
2. CIRM Completes Briefing Visit to Stemedica Cell Technologies
3. Renowned Stem Cell Researcher Files Study Results With Stemedica
4. Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher
5. Sinovac Requests Extension for Annual Shareholders Meeting
6. CryoCor Requests International Trade Commission Investigation Into CryoCath for Patent Infringement
7. deCODE Requests Hearing With Nasdaq Following Receipt of Staff Determination Letter
8. Biotechnology Value Fund, L.P. Requests Avigen Board to Provide Critical Information to Stockholders
9. Xmark Requests That Icagen Oust Its CEO and Pursue Strategic Alternatives, and Calls on Board Members to Resign
10. The West Michigan Science & Technology Initiative is Named Statewide Reviewer for Life Science Funding Requests Through New Program
11. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stemedica Requests Pre-IND Meeting With FDA
(Date:3/29/2017)... -- Research and Markets has announced the addition of ... Forecast to 2025" report to their offering. ... The Global Agricultural Chelates Market ... the next decade to reach approximately $825.4 million by 2025. ... for all the given segments on global as well as regional ...
(Date:3/29/2017)... 29, 2017 /PRNewswire/ - The University of Missouri Research ... business of Sterigenics International, and General Atomics (GA), announce ... to the U.S. Nuclear Regulatory Commission (NRC). This marks ... molybdenum-99 (Mo-99). Once operational, production from this facility will ... for Mo-99, which currently must be imported from outside ...
(Date:3/29/2017)... Research and Markets has announced the ... Markets" report to their offering. ... The study scope includes ... RNA interference, synthetic biology tools and genome editing tools); synthetic ... These technologies and products are analyzed to determine present and ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... the Advancement of Science (AAAS), the world's largest general scientific society and ... high-impact scholarly collection across its cross-platform reference management system. , All six ...
Breaking Biology Technology:
(Date:3/22/2017)... 21, 2017   Neurotechnology , a provider ... today announced the release of the SentiVeillance ... improved facial recognition using up to 10 surveillance, ... computer. The new version uses deep neural-network-based facial ... it utilizes a Graphing Processing Unit (GPU) for ...
(Date:3/22/2017)... , March 21, 2017 Vigilant ... company serving law enforcement agencies, announced today the appointment ... as director of public safety business development. ... law enforcement experience, including a focus on the aviation ... his most recent position, Mr. Sheridan served as the ...
(Date:3/20/2017)... Pa. , March 20, 2017 PMD ... 2.0 personal spirometer and Wellness Management System (WMS), a ... Founded in 2010, PMD Healthcare is a Medical ... with a mission dedicated to creating innovative solutions that ... life. With that intent focus, PMD developed the first ...
Breaking Biology News(10 mins):